Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).
Godet S, Protin C, Dupuis J, Dartigeas C, Bastie JN, Herbaux C, Leblond V, de Guibert S, Ghez D, Brion A, Ysebaert L, Delmer A, Quinquenel A. Godet S, et al. Among authors: brion a. Am J Hematol. 2018 Feb;93(2):E52-E54. doi: 10.1002/ajh.24981. Epub 2017 Dec 4. Am J Hematol. 2018. PMID: 29164674 Free article. No abstract available.
Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience.
Fornecker LM, Aurran-Schleinitz T, Michallet AS, Cazin B, Guieze R, Dilhuydy MS, Zini JM, Tomowiak C, Lepretre S, Cymbalista F, Brion A, Feugier P, Delmer A, Leblond V, Ysebaert L. Fornecker LM, et al. Among authors: brion a. Am J Hematol. 2015 Jun;90(6):511-4. doi: 10.1002/ajh.23999. Epub 2015 Apr 1. Am J Hematol. 2015. PMID: 25752923 Free article. Clinical Trial.
First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.
Meunier G, Ysebaert L, Nguyen-Thi PL, Lepretre S, Quinquenel A, Dupuis J, Lemal R, Aurran T, Tomowiak C, Cymbalista F, Dilhuydy MS, Brion A, Morel P, Cazin B, Leblond V, Cartron G, Ré D, Béné MC, Michallet AS, Feugier P. Meunier G, et al. Among authors: brion a. Hematol Oncol. 2017 Dec;35(4):671-678. doi: 10.1002/hon.2370. Epub 2016 Nov 22. Hematol Oncol. 2017. PMID: 27878835
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
Letestu R, Dahmani A, Boubaya M, Baseggio L, Campos L, Chatelain B, Debliquis A, Drénou B, Jacob MC, Legac E, Le Garff-Tavernier M, Lhoumeau AC, Quiney C, Robillard N, Ticchioni M, Aanei C, Katsahian S, Delepine R, Vaudaux S, Rouillé V, Béné MC, Dartigeas C, Van Den Neste E, Leprêtre S, Feugier P, Cartron G, Leblond V, Lévy V, Cymbalista F; French Innovative Leukemia Organization (FILO). Letestu R, et al. Leukemia. 2021 Jun;35(6):1597-1609. doi: 10.1038/s41375-020-01009-z. Epub 2020 Sep 15. Leukemia. 2021. PMID: 32934355
Does early disease progression predict survival after first line-treatment of Waldenström macroglobulinemia?
Labreuche J, Assouan D, Durot E, Tomowiak C, Roos-Weil D, Toussaint E, Bijou F, Lemal R, Brion A, Laribi K, Ysebaert L, Duhamel A, Morel P; French Innovative Leukaemia Organisation (FILO) Chronic Lymphocytic Leukaemia group. Labreuche J, et al. Among authors: brion a. Hematol Oncol. 2022 Aug;40(3):400-408. doi: 10.1002/hon.2996. Epub 2022 May 1. Hematol Oncol. 2022. PMID: 35385885 Free PMC article.
Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study).
Algrin C, Pérol L, Chapiro E, Baseggio L, Maloum K, Settegrana C, Lesesve JF, Siavellis J, Delmer A, Michallet AS, Ferrant E, Feugier P, Tomowiak C, Brion A, Ghez D, Fornecker LM, Ivanoff S, Struski S, Sutton L, Radford-Weiss I, Eclache V, Lefebvre C, Leblond V, Nguyen-Khac F, Roos-Weil D. Algrin C, et al. Among authors: brion a. Haematologica. 2023 Jun 1;108(6):1691-1696. doi: 10.3324/haematol.2022.282162. Haematologica. 2023. PMID: 36546425 Free PMC article. No abstract available.
Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: efficacy and long-term safety in a single institution.
Brion A, Legrand F, Larosa F, Schillinger F, Garnache-Ottou F, Helias P, Fontan J, Heczko M, Delaby P, Daguindau E, Vuillier J, Chauchet A, Deconinck E. Brion A, et al. Invest New Drugs. 2012 Aug;30(4):1697-702. doi: 10.1007/s10637-011-9632-6. Epub 2011 Jan 13. Invest New Drugs. 2012. PMID: 21229289
Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial.
Brion A, Mahé B, Kolb B, Audhuy B, Colombat P, Maisonneuve H, Foussard C, Bureau A, Ferrand C, Lesesve JF, Béné MC, Feugier P; Groupe Ouest Est d’Etude des Leucémies et autres Maladies du Sang. Brion A, et al. Bone Marrow Transplant. 2012 Apr;47(4):542-8. doi: 10.1038/bmt.2011.117. Epub 2011 Jul 4. Bone Marrow Transplant. 2012. PMID: 21725374 Clinical Trial.
A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.
Olivier G, Clavert A, Lacotte-Thierry L, Gardembas M, Escoffre-Barbe M, Brion A, Cumin I, Legouffe E, Solal-Celigny P, Chabin M, Ingrand P, Colombat P, Delwail V. Olivier G, et al. Among authors: brion a. Am J Hematol. 2014 Nov;89(11):1024-9. doi: 10.1002/ajh.23812. Epub 2014 Aug 27. Am J Hematol. 2014. PMID: 25052698 Free article. Clinical Trial.
139 results